Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series
Nevro Corp. (NYSE: NVRO), a leader in medical devices for chronic pain management, announced its participation in the Wells Fargo 2023 Medtech Innovation Spotlight Call Series on March 24, 2023, at 2:00 pm Eastern Time. Key executives, including D. Keith Grossman (Chairman, CEO), Rod MacLeod (CFO), and Dr. David Caraway (CMO), will provide insights into the company's advancements and solutions like the proprietary 10 kHz Therapy™, which has benefited over 100,000 patients. An archived webcast will be available on Nevro's website for those interested in learning more about their innovative approaches to chronic pain treatment.
- None.
- None.
Friday, March 24, 2023 at 2:00 pm Eastern Time
REDWOOD CITY, Calif., Feb. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, Rod MacLeod, Chief Financial Officer, and Dr. David Caraway, Chief Medical Officer, will participate in the Wells Fargo 2023 Medtech Innovation Spotlight Call Series on Friday, March 24, 2023 at 2:00 pm Eastern Time.
A webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in Redwood City, California, Nevro is a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The company started with a simple mission to help more patients suffering from debilitating pain and developed its proprietary 10 kHz Therapy™, an evidence-based, non-pharmacologic innovation that has impacted the lives of more than 100,000 patients globally. Nevro's comprehensive HFX™ spinal cord stimulation (SCS) platform includes a Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy.
Senza®, Senza II®, Senza Omnia™, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.
Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Chief Corp Communications and Investor Relations Officer
650-433-3247 | julie.dewey@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-to-participate-in-wells-fargo-2023-medtech-innovation-spotlight-call-series-301754718.html
SOURCE Nevro Corp.
FAQ
What is Nevro's participation in the Wells Fargo 2023 Medtech Innovation Spotlight Call Series?
Who are the key executives speaking at the Wells Fargo event for NVRO?
What is the proprietary therapy introduced by Nevro Corp.?
Where can I access the webcast of Nevro's presentation?
What solutions does Nevro offer for chronic pain management?
